ResMed price target raised to $195 from $180 at Mizuho

Mizuho raised the firm’s price target on ResMed to $195 from $180 and keeps a Buy rating on the shares. The company’s fiscal Q2 results were “enough to stick the landing on moderated expectations,” the analyst tells investors in a research note. The firm believes the stock :appears set for relief trade” ahead of the SURMOUNT data.